EUCTR2008-001736-12-IE进行中（未招募）不适用
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients, age =18 years
- •2. Able to comply with the protocol
- •3. Patients must be able to take oral medication
- •4. Histologically documented inoperable, locally advanced or metastatic (stage IIIB and stage IV) NSCLC. (NOTE: Sputum cytology alone is not acceptable). Tumors with
- •mixed histology should be categorized according to the predominant cell type
- •5. Prior Treatment: Failed at least one, but no more than two standard chemotherapy regimens
- •6. Patients who have received maintenance chemotherapy between initial course of therapy (first line) and study entry may enter on the study provided they have not been treated with an agent that targets EGFR or IGF-1R
- •7. Formalin fixed paraffin embedded tumor tissue samples from initial or subsequent diagnosis representative of the disease must be available for shipment to Roche prior to randomization
- •8. Measurable disease according to RECIST
- •9. ECOG performance status 0-2
- •10. Life expectancy > 12 weeks
- •11. Adequate hematological function : ANC =1.5 x 10 exp9/L; platelets =100 x 10 exp9/L, Hb =9 g/dL
- •12. INR =1.5 and PTT =1.5 x ULN unless receiving anticoagulant therapy
- •13. Adequate liver function: Serum bilirubin =1.5 x ULN; transaminases =2.5 x ULN (in case of liver metastases <5 x ULN)
- •14. Adequate renal function: Serum creatinine = 1.5 X ULN
- •15. Serum calcium = 1.1 X ULN
- •16. HbA1c = 7%
- •17. Negative pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 2 years after the onset of menopause
- •18. Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients must have had a head CT/MRI to evaluate for CNS metastasis within 28 days prior to enrollment. Patients with active CNS lesions are excluded. Patients with
- •radiographically stable, asymptomatic previously irradiated lesions are eligible provided patients is = 4 weeks beyond completing cranial irradiation and = 3 weeks off corticosteroid therapy
- •2. Prior treatment with an investigational or commercial agent that acts via IGF-1R inhibition
- •3. Prior treatment with an agent that acts via EGFR targeting
- •4. Administration of any anti-cancer therapies other than those administered in this study during protocol treatment
- •5. Administration of high doses of systemic corticosteroids. High dose is considered as > 20 mg of dexamethasone a day (or equivalent) for > 7 consecutive days. Dexamethasone may induce CYP3A4 activity. CYP3A4 inhibitors and inducers may influence the plasma level of erlotinib
- •6. Prior irradiation: 1) Radiotherapy given within the last 4 weeks prior to first dose of study treatment. 2) Palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to the first dose of study treatment
- •7. Prior Surgery: Surgery (including open biopsy) or significant traumatic injury within the last 2 weeks prior to first dose of study treatment or anticipation of the need for
- •major surgery during study treatment
- •8. Patients must have recovered from any toxic effects of previously administered therapies and must be randomly assigned to study treatment at least 21 days after
- •chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine)
- •9. Lactating women
- •10. Fertile men or women of childbearing potential not using effective methods to prevent pregnancy
- •11. Other active cancer requiring treatment
- •12. Known hypersensitivity to any of the study drugs or their excipients
- •13. Any disease (including psychotic disorders, drug abuse, active infection, uncontrolled hypertension, clinically significant cardiovascular disease for example CVA (= 6 months before randomization), myocardial infarction (= 6 months before randomization), unstable angina, NYHA = grade 2 CHF, arrhythmia requiring medication, hepatic, renal or metabolic disease (including uncontrolled diabetes
- •mellitus), metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the
- •use of an investigational drug or puts the patient at high risk for treatment-related complications
- •14. History of allogeneic bone marrow transplantation or organ transplantation
- •15. Any known significant ophthalmologic abnormalities of the surface of the eye (the use of contact lenses is not recommended)
- •16. No dysphagia or active gastrointestinal disease or disorder that alters gastrointestinal motility or absorption; no lack of integrity of the gastrointestinal tract (e.g. as significant surgical resection of the stomach or small bowel). Patients unable to swallow intact tablets must be able to swallow tablets dissolved in water
- •17. Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to starting study treatment
研究者
相似试验
进行中（未招募）
不适用
A Randomized, double blind study to determine the effect oftwo dose schedules of R1507 or placebo, both in combinationwith erlotinib (Tarceva), on progression-free survival inpatients with advanced non-small cell lung cancer with diseaseprogression after first or second line chemotherapy. - NDClinical stage IIIb/IV Non-small cell lung cancer with diseaseprogression following at least one but no more than two standardchemotherapy regimensMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2008-001736-12-ITROCHE150
进行中（未招募）
不适用
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyTo investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have failed at least one, but no more than two standard chemotherapy regimens. The study will also investigate 2 doses and schedules of R1507 combined with erlotinib compared with erlotinib and placebo, and assess the safety and tolerability of the combination in this patient population.MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-001736-12-ATF. Hoffmann-La Roche Ltd150
进行中（未招募）
1 期
A Randomized, double blind study to determine the effect of two dose schedules ofR1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-freesurvival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapyEUCTR2008-001736-12-FRF. Hoffmann-La Roche Ltd150
已完成
不适用
Comparison of how well allopathic and herbal medicine work for the treatment of Entamoeba histolyticaAmoebiasisInfections and InfestationsISRCTN10942146Hamdard University (Pakistan)202
进行中（未招募）
1 期
A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetesEUCTR2016-003477-18-DEniversity Hospital Tuebingen40